PMID- 34589577
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211001
IS  - 2372-7705 (Print)
IS  - 2372-7705 (Electronic)
IS  - 2372-7705 (Linking)
VI  - 22
DP  - 2021 Sep 24
TI  - LRPPRC regulates metastasis and glycolysis by modulating autophagy and the 
      ROS/HIF1-alpha pathway in retinoblastoma.
PG  - 582-591
LID - 10.1016/j.omto.2021.06.009 [doi]
AB  - Retinoblastoma (RB) is the most common intraocular tumor among children. 
      Leucine-rich pentatricopeptide repeat (PPR)-motif-containing protein (LRPPRC), a 
      suppressor gene of autophagy, has been proven to play a regulatory role in tumor 
      progression. However, little is known about functional roles and mechanisms of 
      LRPPRC in RB progression. First, we performed a detailed analysis for RB and 
      normal control. The expression of LRPPRC in the RB tissues was significantly 
      higher than that in normal tissues. Moreover, LRPPRC suppression could repress 
      tumor cell migration, invasion, glycolysis, and reactive oxygen species 
      (ROS)/hypoxia-inducible factor-1alpha (HIF1-alpha) pathway activation by mediating 
      autophagy. Furthermore, overexpression of HIF1-alpha partially reversed the above 
      changes induced by LRPPRC knockdown. The regulation of LRPPRC on tumor metastasis 
      and glycolysis was also validated by a xenograft tumor assay. In summary, LRPPRC 
      could regulate metastasis and glycolysis of RB by mediating autophagy suppression 
      and further activating the ROS/HIF1-alpha pathway, and LRPPRC could be a promising 
      prognostic biomarker for RB.
CI  - (c) 2021 The Authors.
FAU - Song, Kun
AU  - Song K
AD  - Department of Gastrointestinal Surgery, Xiangya Hospital, Central South 
      University, Changsha 410008, Hunan Province, China.
FAU - Li, Bin
AU  - Li B
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, Changsha 410008, Hunan Province, China.
FAU - Chen, Ying-Ying
AU  - Chen YY
AD  - Department of Ophthalmology, Hainan General Hospital, Haikou 570000, Hainan 
      Province, China.
FAU - Wang, Hua
AU  - Wang H
AD  - Eye Center of Xiangya Hospital, Central South University, Changsha 410008, Hunan 
      Province, China.
AD  - Hunan Key Laboratory of Ophthalmology, No. 87 Xiangya Road, Kaifu District, 
      Changsha 410008, Hunan Province, China.
FAU - Liu, Kang-Cheng
AU  - Liu KC
AD  - Eye Center of Xiangya Hospital, Central South University, Changsha 410008, Hunan 
      Province, China.
AD  - Hunan Key Laboratory of Ophthalmology, No. 87 Xiangya Road, Kaifu District, 
      Changsha 410008, Hunan Province, China.
FAU - Tan, Wei
AU  - Tan W
AD  - Eye Center of Xiangya Hospital, Central South University, Changsha 410008, Hunan 
      Province, China.
AD  - Hunan Key Laboratory of Ophthalmology, No. 87 Xiangya Road, Kaifu District, 
      Changsha 410008, Hunan Province, China.
FAU - Zou, Jing
AU  - Zou J
AD  - Eye Center of Xiangya Hospital, Central South University, Changsha 410008, Hunan 
      Province, China.
AD  - Hunan Key Laboratory of Ophthalmology, No. 87 Xiangya Road, Kaifu District, 
      Changsha 410008, Hunan Province, China.
LA  - eng
PT  - Journal Article
DEP - 20210624
PL  - United States
TA  - Mol Ther Oncolytics
JT  - Molecular therapy oncolytics
JID - 101666776
PMC - PMC8450181
OTO - NOTNLM
OT  - LRPPRC
OT  - ROS/HIF1-alpha pathway
OT  - autophagy
OT  - glycolysis
OT  - metastasis
OT  - retinoblastoma
COIS- The authors declare no competing interests.
EDAT- 2021/10/01 06:00
MHDA- 2021/10/01 06:01
PMCR- 2021/06/24
CRDT- 2021/09/30 07:18
PHST- 2021/01/07 00:00 [received]
PHST- 2021/06/10 00:00 [accepted]
PHST- 2021/09/30 07:18 [entrez]
PHST- 2021/10/01 06:00 [pubmed]
PHST- 2021/10/01 06:01 [medline]
PHST- 2021/06/24 00:00 [pmc-release]
AID - S2372-7705(21)00089-9 [pii]
AID - 10.1016/j.omto.2021.06.009 [doi]
PST - epublish
SO  - Mol Ther Oncolytics. 2021 Jun 24;22:582-591. doi: 10.1016/j.omto.2021.06.009. 
      eCollection 2021 Sep 24.